Principal Investigator

Gregory A
Masters
Awardee Organization

Christiana Care Health Services, Inc.
United States

Fiscal Year
2023
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

Delaware Christiana Care NCORP

Delaware/Christiana Care (CCHS) National Cancer Institute Oncology Research Program (NCORP) was originally funded as a Community Clinical Oncology Program (CCOP) in 1987, was funded as a NCI Community Cancer Centers Program (NCCCP) beginning in 2007 and continued participation as an NCORP in 2014 through the present. CCHS has been an exemplary contributor to all programs, frequently recognized for high accruals,stellar data quality and timeliness of submissions. Currently, CCHS participates in the ALLIANCE, ECOGACRIN, NRG, Wake Forest and Rochester cooperative groups with approximately 80 trials opened to accrual. Participation in CTSU and the CIRB is active and ongoing. Our catchment area includes all of Delaware and portions of New Jersey, northeastern Maryland and southeastern Pennsylvania. Our NCORP includes two affiliates, Beebe Health Care and Nanticoke Memorial, both located in southern Delaware. Our communities represents a popluation base in excess of 2 million people with extensive protocol entry potential. Under the leadership of Gregory Masters, M.D, Principal Investigator and Kandie Dempsey, DBA, MS, RN, OCN, Director, NCORP investigators and support professionals will continue to participate in NCTN core committees and leadership positions. Currently, our physician researchers are represented with appointments to 17 NCORP committees and 3 NCI Steering Committees (Breast, Gynecological and Imaging). Our mission is to continue accruals to both treatment and cancer control studies and to further develop Cancer Care Delivery Research (CCDR) participation which will build upon the intiatives set forth with our collaboration the NCI. Every patient at the Helen F. Graham Cancer Center & Research Institute (HFGCCRI) is evaluated for clinical trial participation. We anticipate dedicating at minimum 10% of our activities towards CCDR to include scientific investigation of the complexities of social factors, organizational structures and processes, health technologies, access to cancer care, quality and cost factors, disparties in our community. And will examine the feasibility of examining financial costs of care and health technology systems as part of the CCDR program. The overall impact of this grant will be to ensure continuation and stimulate expansion of NCORP activities, including treatment and cancer control research, at CCHS and its affiliates. The Delaware/CCHS NCORP has consistently rated amongst top in the nation for clinical trial accruals. Over the past three years the accrual rate has been 21.1% in 2015, 26.3% in 2016 and 27.4% in 2017.

Publications

  • Barginear M, Dueck AC, Allred JB, Bunnell C, Cohen HJ, Freedman RA, Hurria A, Kimmick G, Le-Rademacher JG, Lichtman S, Muss HB, Shulman LN, Copur MS, Biggs D, Ramaswamy B, Lafky JM, Jatoi A. Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101. The oncologist. 2019 May;24(5):617-623. Epub 2018 Nov 8. PMID: 30409792
  • Masters GA, Wang X, Hodgson L, Shea T, Vokes E, Green M. A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531. Lung cancer (Amsterdam, Netherlands). 2011 Nov;74(2):258-63. Epub 2011 May 6. PMID: 21529989
  • Chakravarthy AB, Zhao F, Meropol NJ, Flynn PJ, Wagner LI, Sloan J, Diasio RB, Mitchell EP, Catalano P, Giantonio BJ, Catalano RB, Haller DG, Awan RA, Mulcahy MF, O'Brien TE, Santala R, Cripps C, Weis JR, Atkins JN, Leichman CG, Petrelli NJ, Sinicrope FA, Brierley JD, Tepper JE, O'Dwyer PJ, Sigurdson ER, Hamilton SR, Cella D, Benson AB 3rd. Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204). The oncologist. 2020 May;25(5):e798-e807. Epub 2019 Dec 18. PMID: 31852811
  • Argiris A, Li S, Savvides P, Ohr JP, Gilbert J, Levine MA, Chakravarti A, Haigentz M Jr, Saba NF, Ikpeazu CV, Schneider CJ, Pinto HA, Forastiere AA, Burtness B. Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Dec 1;37(34):3266-3274. Epub 2019 Oct 16. PMID: 31618129
  • Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, Villaflor VM, Cohen SJ, Mayer RJ, Venook A, Benson AB 3rd, Goldberg RM. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Aug 10;34(23):2736-42. Epub 2016 Jul 5. PMID: 27382098
  • Varlotto JM, Sun Z, Ky B, Upshaw J, Katz SI, Fitzgerald TJ, Wakelee H, Diehn M, Mankoff DA, Lovely C, Belani C, Oettel K, Masters G, Ramalingam S, Pennell NA. A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study. The oncologist. 2021 Jun;26(6):523-532. Epub 2021 Mar 11. PMID: 33594771
  • Comstock CE, Gatsonis C, Newstead GM, Snyder BS, Gareen IF, Bergin JT, Rahbar H, Sung JS, Jacobs C, Harvey JA, Nicholson MH, Ward RC, Holt J, Prather A, Miller KD, Schnall MD, Kuhl CK. Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening. JAMA. 2020 Feb 25;323(8):746-756. PMID: 32096852
  • Martin P, Jung SH, Pitcher B, Bartlett NL, Blum KA, Shea T, Hsi ED, Ruan J, Smith SE, Leonard JP, Cheson BD. A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Nov 1;28(11):2806-2812. PMID: 28945884
  • Rosenberg JE, Ballman KA, Halabi S, Atherton PJ, Mortazavi A, Sweeney C, Stadler WM, Teply BA, Picus J, Tagawa ST, Katragadda S, Vaena D, Misleh J, Hoimes C, Plimack ER, Flaig TW, Dreicer R, Bajorin D, Hahn O, Small EJ, Morris MJ. Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Aug 1;39(22):2486-2496. Epub 2021 May 14. PMID: 33989025
  • Naughton MJ, Liu H, Seisler DK, Le-Rademacher J, Armer JM, Oliveri JM, Sloan JA, Hock K, Schwartz M, Unzeitig G, Melnik M, Yee LD, Fleming GF, Taylor JR, Loprinzi C, Paskett ED. Health-related quality of life outcomes for the LEAP study-CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients. Cancer. 2021 Jan 15;127(2):300-309. Epub 2020 Oct 20. PMID: 33079393
  • Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. The New England journal of medicine. 2016 Jul 14;375(2):134-42. PMID: 27410922
  • Basch E, Dueck AC, Rogak LJ, Minasian LM, Kelly WK, O'Mara AM, Denicoff AM, Seisler D, Atherton PJ, Paskett E, Carey L, Dickler M, Heist RS, Himelstein A, Rugo HS, Sikov WM, Socinski MA, Venook AP, Weckstein DJ, Lake DE, Biggs DD, Freedman RA, Kuzma C, Kirshner JJ, Schrag D. Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA oncology. 2017 Aug 1;3(8):1043-1050. PMID: 28208174
  • Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O'Connor T, Velasco MR Jr, Weckstein D, O'Mara A, Loprinzi CL, Shapiro CL. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA. 2017 Jan 3;317(1):48-58. PMID: 28030702
  • Vij R, Le-Rademacher J, Laumann K, Hars V, Owzar K, Shore T, Vasu S, Cashen A, Isola L, Shea T, DeMagalhaes-Silverman M, Hurd D, Meehan K, Beardell F, Devine S. A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance). Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2019 Oct;25(10):1984-1992. Epub 2019 Jun 15. PMID: 31212080
  • Shapiro CL, Moriarty JP, Dusetzina S, Himelstein AL, Foster JC, Grubbs SS, Novotny PJ, Borah BJ. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Dec 10;35(35):3949-3955. Epub 2017 Oct 12. PMID: 29023215
  • Hwang ES, Hyslop T, Hendrix LH, Duong S, Bedrosian I, Price E, Caudle A, Hieken T, Guenther J, Hudis CA, Winer E, Lyss AP, Dickson-Witmer D, Hoefer R, Ollila DW, Hardman T, Marks J, Chen YY, Krings G, Esserman L, Hylton N. Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Apr 20;38(12):1284-1292. Epub 2020 Mar 3. PMID: 32125937
  • Holstein SA, Suman VJ, Owzar K, Santo K, Benson DM Jr, Shea TC, Martin T, Silverman M, Isola L, Vij R, Cheson BD, Linker C, Anderson KC, Richardson PG, McCarthy PL. Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2020 Aug;26(8):1414-1424. Epub 2020 Apr 20. PMID: 32325171
  • Paskett ED, Le-Rademacher J, Oliveri JM, Liu H, Seisler DK, Sloan JA, Armer JM, Naughton MJ, Hock K, Schwartz M, Unzeitig G, Melnik M, Yee LD, Fleming GF, Taylor JR, Loprinzi C. A randomized study to prevent lymphedema in women treated for breast cancer: CALGB 70305 (Alliance). Cancer. 2021 Jan 15;127(2):291-299. Epub 2020 Oct 20. PMID: 33079411
  • Galanis E, Anderson SK, Twohy EL, Carrero XW, Dixon JG, Tran DD, Jeyapalan SA, Anderson DM, Kaufmann TJ, Feathers RW, Giannini C, Buckner JC, Anastasiadis PZ, Schiff D. A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872. Cancer. 2019 Nov 1;125(21):3790-3800. Epub 2019 Jul 10. PMID: 31290996
  • Rosenbaum CA, Jung SH, Pitcher B, Bartlett NL, Smith SM, Hsi E, Wagner-Johnston N, Thomas SP, Leonard JP, Cheson BD. Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance). British journal of haematology. 2019 Apr;185(1):53-64. Epub 2019 Feb 5. PMID: 30723894
  • Uy GL, Mandrekar SJ, Laumann K, Marcucci G, Zhao W, Levis MJ, Klepin HD, Baer MR, Powell BL, Westervelt P, DeAngelo DJ, Stock W, Sanford B, Blum WG, Bloomfield CD, Stone RM, Larson RA. A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood advances. 2017 Jan 24;1(5):331-340. PMID: 29034366
  • Bradbury AR, Lee JW, Gaieski JB, Li S, Gareen IF, Flaherty KT, Herman BA, Domchek SM, DeMichele AM, Maxwell KN, Onitilo AA, Virani S, Park S, Faller BA, Grant SC, Ramaekers RC, Behrens RJ, Nambudiri GS, Carlos RC, Wagner LI. A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152). Cancer. 2022 Apr 1;128(7):1381-1391. Epub 2021 Dec 10. PMID: 34890045
  • Bogart J, Wang X, Masters G, Gao J, Komaki R, Gaspar LE, Heymach J, Bonner J, Kuzma C, Waqar S, Petty W, Stinchcombe TE, Bradley JD, Vokes E. High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 May 1;41(13):2394-2402. Epub 2023 Jan 9. PMID: 36623230